Join PATH at the 35th International Papillomavirus Conference
At the 35th International Papillomavirus Conference (IPVC), PATH will present findings from recent human papillomavirus (HPV) vaccine projects, exchange learnings with partners, and share more about our efforts to accelerate HPV vaccine research and delivery.
Cervical cancer is a leading cause of cancer death among women in low- and middle-income countries (LMICs) and almost all cases can be attributed to HPV.
HPV vaccines have been licensed for more than 15 years and are the primary prevention tool to accelerate cervical cancer elimination. These vaccines are safe and highly effective, and the World Health Organization (WHO) recommends their introduction in all national immunization programs.
For decades, PATH has been at the forefront of evidence-based strategies, from HPV vaccine research and delivery to cervical cancer screening and treatment, to ensure we best meet LMICs' needs for the greatest health impact.
The theme of IPVC 2023, which will be held April 17-21 in Washington, D.C., is “Coming Together for HPV Elimination.” PATH presenters will share findings from recent projects that are firmly aligned with this theme.
Three presentations will share different aspects of results from an HPV vaccine cost of delivery study conducted with partners in Ethiopia, Guyana, Rwanda, Senegal, Sri Lanka, and Uganda. This study sought to address the limitations of existing HPV vaccine delivery costing studies by estimating the ongoing delivery costs in these six countries and to explore the operational context for the program.
IPVC will also heavily feature evidence and updates related to the HPV vaccine landscape, including single-dose HPV vaccination and clinical investigation of other HPV vaccines.
For example, the conference will host a session about the recent WHO endorsement of a single-dose HPV vaccine schedule in the target age group. The Single-Dose HPV Vaccine Evaluation Consortium, coordinated by PATH, compiled and synthesized the evidence that informed the schedule update and continues to provide evidence-based resources for policymakers.
Another session will highlight interim results from a study of Cecolin®—Xiamen Innovax Biotech Co.’s bivalent HPV vaccine that received WHO prequalification in 2021—investigating the vaccine’s performance in low- and middle-income settings, as well as exploring alternative and extended dosing schedules for HPV vaccine.
See below for a schedule of PATH’s presentations at the conference. (All times listed in Eastern Daylight Time.)
Evaluating the Ongoing Costs of HPV Vaccine Delivery in Mature Programs: Evidence From Guyana, Rwanda, Uganda, Ethiopia, Senegal, and Sri Lanka
April 21, 2023
10:00 - 11:30 a.m.
Room: Ballroom C
Presenter: Mercy Mvundura
Lecture Time: 10:00 - 10:10 a.m.
Innovax Bivalent HPV Vaccine: Safety and Immunogenicity of One- and Two-Dose of Cecolin® Versus Gardasil® in Girls 9-14 Years - Phase III Interim Data
April 20, 2023
10:30 a.m. - 12:00 p.m.
Presenter: Anne Schuind
Lecture Time: 11:40 - 11:50 a.m.
Evaluating the Potential Program Cost Savings with a Single-Dose HPV Vaccine Schedule: Health-facility level estimates
Poster Discussion (Short Oral Session) - Public Health 01
April 18, 2023
10:00 - 10:30 a.m.
Room: Exhibition Area
Presenter: Rose Slavkovsky
Lecture Time: 10:10 - 10:15 a.m.
One Size Does Not Fit All: Comparison of HPV Vaccine Delivery in Guyana, Rwanda, Uganda, Ethiopia, Senegal, and Sri Lanka, 2019
Poster Viewing - Shift 01
April 18, 2023
7:00 a.m. - 5:00 p.m.
Room: Exhibition Area
Presenter: D. Scott LaMontagne